Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

232 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-01

Study Completion Date

2026-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Paraneoplastic neurological syndromes are rare syndromes caused by the remote effects of cancer. They have an immune-mediated pathogenesis, yet the underlying mechanisms are not fully elucidated. CV2/Collapsin response-mediator protein 5 (CRMP5)-IgG paraneoplastic neurological syndrome is characterized by heterogeneous clinical presentations, affecting both central and peripheral nervous system, and the most frequently associate tumor is small cell lung carcinoma. Central nervous system involvement along with CSF and neuroimaging findings have not been fully described in the literature in CV2/CRMP5 patients. Unraveling the complexities of CV2/CRMP5 paraneoplastic neurological syndrome is critical to improve diagnosis, treatment, and patients' care. Our intention is to perform a comprehensive analysis of the clinical characteristics and instrumental investigations of a large cohort of CV2/CRMP5 patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tumor Characteristics in Patients With Paraneoplastic Neurological Syndromes (PNS)

NCT03963700

Cancer Paraneoplastic Syndromes Neurologic Disorder +2 more

UNKNOWN

Clinical Characterization and Outcome of Anti-IgLON5 Disease

NCT06131346

Anti-IgLON5 Disease

RECRUITING

Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma

NCT01305122

OMS Grade II Glioma

TERMINATED NA

CSF Proteomic Characterization of Glioblastomas

NCT06845020

Glioblastoma Glioblastoma WHO Grade IV Glioblastoma (GBM) +2 more

NOT_YET_RECRUITING

Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours

NCT00213876

Oligodendrogliomas

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CV2 Autoimmunity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with CV2 Abs

Patients harboring CV2 Abs and a paraneoplastic neurological syndromes.

Description of clinical, immunological and tumor features of patients harboring CV2 Abs

Intervention Type OTHER

This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Description of clinical, immunological and tumor features of patients harboring CV2 Abs

This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.

Intervention Type OTHER